Hypertension Research
In Pregnancy

1

REVIEW

A review of current practice in using
Balloon Tamponade Technology in
the management of postpartum
haemorrhage
Christos Georgiou1,2
1

Faculty Science, Medicine and Health, Graduate School of Medicine, University of

Wollongong, 2Wollongong Hospital, Australia

C. Georgiou

Reprint request to:
Christos Georgiou, BSc (Hons.),
Ph.D., MBBS, MRCOG, FRANZCOG,
The Wollongong Hospital
Academic Suite, Wollongong
Hospital, Block C, Level 8, Crown
Street, Wollongong, NSW, 2500,
Australia.
E-mail: georgiou@uow.edu.au
Key words:
balloon tamponade technology,
indications, intrauterine,
management, mechanisms,
postpartum haemorrhage, review,
vaginal
Received: February 14, 2014
Revised: February 24, 2014
Accepted: March 22, 2014

The use of various Balloon tamponade technologies has steadily increased over the last five years in the management
of postpartum haemorrhage. New methodologies and applications have been included beyond the original descriptions.
Furthermore, novel approaches and mechanisms of action have also been suggested.
No comparative trials involving “uterine/fertility sparing” approaches such as Balloon Tamponade Technology have
been performed comparing the safety, efficiency and long term effects on endometrial and myometrial functions.
However, balloon tamponade technology is rapidly becoming accepted as a preferred second line approach following
failed first line uterotonics in many obstetric units.
This paper reviews the current use of various balloon tamponade technologies in the management of postpartum
haemorrhage.

Background
Obstetric haemorrhage is a significant contributor to
worldwide maternal morbidity and mortality (MMM).1,2)
Since the WHO millennium Goal directives, the relative
position that this specific direct cause of MMM occupies,
has recently improved in some countries.3) For example
in the United Kingdom (UK) from 1985–2005, direct
maternal deaths from postpartum haemorrhage (PPH)
usually occupied position three.4) In the latest United
Kingdom triennial Confidential Enquiry in to Maternal
Deaths (2006–2008), it now occupies position six.5)
Many factors contribute to this ultimate position and in
Japan, recent publications suggest that both maternal age
and place of delivery are closely correlated to the
mortality rate from PPH.6) In the UK a study addressing
specific second-line therapies for PPH suggests another
contributing factor. This is the ubiquitous use of balloon
tamponade in the management of PPH.7)
At present various guidelines for the management
of PPH include the use of uterine balloon tamponade
after the exclusion of retained products and genital tract
trauma.8) In these situations, the balloon is usually used
as a form of treatment following the failed use of first
line uterotonics (FLU) such as oxytocin, ergometrine,

misoprostol and prostaglandin F2α. In such studies
successful balloon tamponade outcomes have been
reported in the range of 80–100%.9,10)
Both uterine specific and non-uterine specific balloons
appear to have been adopted into the armamentarium
of second line approaches (SLA), such as uterine artery
embolisation and compression sutures. However, the
relative hierarchy of balloon tamponade technology
(BTT) use with respect to these other SLA has not been
established.9,10) In addition, the theoretical complications
that exist in association with balloon usage such as:
perforation, necrosis and rupture of the uterus, were
largely based on the use of balloons in other organ
systems such as the oesophagus.11,12) However, with time
complications involving BTT, such as uterine perforation
and uterine rupture, have since been described.13,14)
Finally, the long-term surrogate effects following the
use of BTT, such as subsequent menses, fertility and
pregnancies have only recently been reviewed.15)
The purpose of this paper is to review the various
uterine balloon tamponade technologies available and
how they are currently being used in the management
of PPH.
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Table 1. Specifications of uterine-specific balloon tamponade devices
Manufacturer/Distributor
Contact details
Balloon material
Recommended volume
Drainage of uterine cavity
a

Length of drainage tip (cm)
Balloon number(s) in device
Device shown in Figure 1
*a

Bakri

BT-Cath

EBB

Cook Medical
www.cookgroup.com
Silicone

UTAH Medical Products Inc
www.utahmed.com
Silicone
250 mls (Gastric balloon)
150 mls (Oesophagus balloon)

Glenveigh
www.glenveigh.com
Polyurethane
750 mls (Uterine balloon)
300 mls (Vaginal balloon)

500 mls
Yes
3.6
1
“A”

Umbilicated
1
“B”

Yes
1.7

to balloon edge

2
“C”

, when not inflated.

Balloon tamponade technology
With respect to Obstetrics and Gynaecology, BTT refers
to the use of a balloon-like structure that is insufflated,
usually with saline, within the uterine cavity, and more
recently in the vagina, to create a “tamponade” effect.10)
This technology, that is currently used for both
gynaecological and obstetric bleeding conditions, was
originally used in the management of haemorrhage in
other systems, such as the oesophagus and bladder.16,17)

Uterine specific and non-uterine specific balloons

In addition to the original uterine-specific Bakri balloon
(Cook Medical, Bloomington, Indiana), there are
currently two other uterine-specific balloons: The
BT-Cath (Utah Medical Products Inc. West Midvale,
Utah) and the Ebb two-balloon system (Glenveigh
Medical LLC, Chattanooga, Tennessee) (Figure 1). The
comparative features of these balloons are listed in Table
1.18–20)
In contrast to the Bakri balloon, the BT-Cath contains
a more pronounced umbilicated drainage channel and
the silicone balloon layer is thinner.19) The Ebb system is
fundamentally different from the Bakri balloon and the
BT-Cath, in that it contains a double-balloon system.20)
The proximal balloon of the Ebb balloon, is designed
to be insufflated within the vagina in order to maintain
the distal balloon within the uterine cavity (Figure 1).
Unlike the materials used for other balloons, namely
silicone or latex/rubber, the Ebb balloons are comprised
of thin but durable polyurethane material ( < 1 mm). The
vast majority of published literature involves the Bakri
balloon with minimal publications for the other uterinespecific balloon products.21)
More recently, various “cervical ripening” balloons
(CRB) have been used in the management of PPH
(Figure 2).22) These balloons have recommended balloon
capacities of 40–150 mls, significantly less than that of
the uterine-specific balloons.18–20) Previous studies have
2
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Table 2. Five “Stages” in the use of balloon
tamponade technology in the management of PPH
(Reproduced from Georgiou, 2012.)33)
Stage
1
2
3
4
5

Description
Risk factors, indication for use and location of
insertion
Patient positioning and access to the uterine
cavity
Balloon insufflation and prevention of
displacement
Post-insertion observation and supportive
treatment
Removal of balloon and follow-up

described using small volume balloons, such as the Foley
catheter and the Sengstaken-Blakemore tube (SBT), and
filling them in excess of their recommended volumes in
order to achieve a positive tamponade test.23,24) However,
the intentional use of smaller volumes in achieving
haemostasis involves the concomitant use of other
cervical procedures such as: cervical suturing or use of
a vaginal pack, essentially preventing the balloon from
being displaced.22,25) However, they potentially prevent
blood loss through the cervical canal and this may
contribute to their ultimate mechanism of action (See
“Mechanisms of action” below).

Balloon volume and the tamponade test

The initial “balloon” used for the management of PPH
was in fact a group of eight silicone Foley catheters, each
of which was filled with 35–75 mls of N-saline.26) The
subsequently designed Bakri “SOS” (Surgical Obstetric
Silicone) balloon could accommodate 500 mls, but there
does not appear to be any specific data why 500 mls was
chosen as the balloon capacity.27) However, the literature
has provided examples of volumes ranging from
50–1500 mls N-saline that have been effective in
controlling bleeding from an atonic uterus.10,28,29) Studies
evaluating balloon volume and pressure relationships
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Figure 1. Uterine specific balloons.
(A) Bakri balloon, (B) BT-Cath balloon, (C) EBB balloon.
The double balloon system of the EBB balloon has a
balloon for the uterine cavity (u) and a balloon for the
vagina (v). All balloons have a drainage channel (*) and
insufflation systems ( + ). Bar = 5 cm (Reproduced and
modified from Georgiou, 2012.)31)
within the uterus clearly identify uterine compliance as an
inherent variable to the final uterine volume necessary to
stop bleeding.30,31) As there is no obvious method of
assessing uterine compliance, guestimating the required
volume in order to achieve haemostasis without
integrating a clinical evaluation during insufflation, may
result in a negative tamponade test.31)

Practical considerations of use
Incorporation of BTT into PPH protocols has been
reported in published guidelines during the management
of PPH.32) Practical and theoretical “stages of use” have
also been described in order to facilitate appropriate
integration into a suitable management plan. This
involves a five-step approach to help with training, audit
and root-cause analysis of complications involved in
using BTT (Table 2).33)
It has been suggested that, in addition to the timing that
interventions are instigated in the management of PPH,
differences in methodologies may also contribute to the
overall success rate.7,33) Some of these methodological
variants include: method of insertion of the balloon into
the uterine cavity (anterograde or retrograde), filling
methods and prevention of balloon displacement.

Figure 2. Cervical ripening balloons used in Japan.
(A) “Mini-metro” (mini-metreurynter). Maximum volume
40 mls, (Soft medical. Co. Ltd., Tokyo, Japan). (B)
“Fujimetoro”. Maximum Volume 500 mls, (Fuji Latex Co.
Ltd., Tochigi, Japan). Bar = 2.5 cm

Insertion of balloon

Various approaches of balloon insertion have been
documented.10) In some studies the balloon is inserted via
a transvaginal (anterograde) direction. In others, the
balloons are inserted in a transabdominal (retrograde)
direction via the lower segment uterine incision during
the caesarean section (CS).33) There are also clinicallybased approaches, whereby the initial decision to use a
Bakri balloon may occur intra-operatively during a CS.
However, following uterine incision closure, this decision
is later modified dependant on the evaluation of ongoing
blood loss from the vagina. If bleeding continues then the
balloon is inserted transvaginally.31,33) The theoretical
differences in time between decision-to-insufflation of the
balloon using either approach is similar. However,
re-evaluation from the vaginal aspect allows for
abandonment of balloon use, as closure of the uterus may
in-of-itself be sufficient in achieving haemostasis.
Transabdominal insertion requires specific
considerations with respect to the proximal design of
the balloon shaft particularly with respect to the ease
of insertion through an undilated cervix.10) For example
during CS for the presence of placenta praevia (Figure 1
and 3).34) In one case involving placenta praevia/accreta,
the proximal end of the balloon was drained via the
abdomen.35)

Rapid insuﬄation of the balloon

The initial methodology by which the balloons were
insufflated involved multiple exchanges of N-Saline filled
syringes until the required volume was achieved.18) The
“required” volume is either based on the “Tamponade
test” or alternatively “predetermined”.36,37) Some balloon
manufacturers have since modified the filling process of
their devices.19,37) These so-called “rapid instillation
components” or Easyfill modifications enable the
balloons to be filled without the repetitive nature of
alternating syringes. Although no data is available to
suggest that delay in filling the balloon results in an
increase maternal morbidity, the advantage in the rapidity
Hypertens Res Pregnancy 2014; 2: 1–10
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Figure 3. Proximal components of tamponade balloons.
* represents proximal point of measurement of balloon shaft; b,d,e,f,i,j,k and m indicate
insufflation portion of balloon; a,c,g, and h indicate drainage portion of uterine cavity. Note
l and n do not contribute to balloon tamponade or drainage. They inflate a balloon within
the actual tamponade balloon. There is no drainage of the uterine cavity when using the
Rusch and Condom-Catheter. (Reproduced from Georgiou, 2009.)10)
of filling is that the recommended maximum balloon
volume is reached sooner. Therefore, if a “negative
tamponade test” results, the necessary subsequent steps
are expediated.36) Use of these “rapid-filling” modifications
does not necessarily result in an increase in positive
clinical-based outcomes (i.e. a positive tamponade
method). However, they may result in “over-distending”
the uterus by insufflating “blindly” if a concurrent clinical
evaluation of the insufflation process does not occur.
The hypothetical risks of “over-distension” and
“pressure” effects on the endometrium and myometrium
secondary to filling are difficult to address as a term
uterus can achieve a volume capacity that exceeds 400
mls.38) However, over-distension may have contributed
to uterine rupture and subsequent hysterectomies in two
cases of PPH in which BTT was used.13,14) Intuitively,
although this risk may be considered to be lower
following a vaginal delivery with no previous CS, the
risk in an “unscared” uterus is unlikely to be negligible.
Prevention of balloon displacement
One of the common difficulties encountered when a
balloon is inserted into the postpartum uterus, is balloon
migration from the original fundal cavity location.29) This
is particularly problematic in cases of balloon usage
following a vaginal delivery or CS at full, or near-full,
cervical dilatation.34)
The displacement is due to the lower segment area
having greater compliance in comparison to the uterine
fundus. In addition, the uterus is rarely completely atonic
and fundal contractions may occur, even though they may
not necessarily result in haemostasis. This uterine activity
4
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may be elicited by the use of concurrent uterotonics or
secondary to uterine/cervical stretching caused by the
insufflated balloon.30,39)
The original descriptions using BTT involved the use
of the balloon following a CS.18) The balloon therefore,
could be placed on traction following trans-abdominally
insertion at CS. This further facilitated haemostasis
by applying contact to the placental bed as the cases
involved placenta praevia. Subsequent publications in
which the balloon was used following vaginal deliveries,
proposed vaginal packing with gauze in order to maintain
the balloon in the uterine cavity.29)
The two-balloon system of the Ebb balloon is one
possible solution to the balloon displacement problem.
The proximal balloon is inflated in the vagina to maintain
the distal balloon within the uterine cavity. However,
others advocate the use of vacuum connected to the
balloon drainage channel to maintain the balloon within
the uterine cavity, transfixing the distal tip of the balloon
shaft through the uterine fundus and out through the
abdomen or suturing/clamping the cervix around the
balloon shaft.25,30,40,41)
Images in some of these displaced examples depict
the balloon in the lower segment, but the balloon is not
necessarily out of the uterus. Although this is sometimes
referred to as “incorrect positioning of the balloon”,
the majority of these cases do not require balloon
re-deployment, as bleeding is often controlled.42) One
explanation is that haemostasis was achieved prior to
displacement. However, others explanations include a
mechanism of action at the level of the uterine arteries or
cervical/lower uterine segment mediating uterine activity
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(See Mechanisms of action below).

New indications for use
Since the initial studies of the BTT, there has been a
steady increase in the number of publications involving
both non-uterine and uterine specific balloons.
Furthermore, case series data suggest a significant
reduction in invasive procedures and potential benefits in
low resource settings.32,43)
Although studies have used BTT as a treatment
modality for bleeding in the management of uterine
atony, recently the balloons have also been used in other
circumstances. These include: (1) Prophylaxis of PPH in
cases of placenta praevia, (2) For the treatment for PPH
secondary to vaginal lacerations, (3) In the prevention
of recurrent uterine inversion, (4) In the absence of
blood resources and facilitating the transfer of patients
to tertiary centres, (5) In the presence of DIC secondary
to excessive blood loss and (6) During a negative
tamponade test.

Prophylactic use

Foley catheters, SBT and the Bakri balloon have been
used in the management of PPH after delivery in cases of
placenta praevia.18,44,45) However, the concept of using
BTT in order to prevent PPH following delivery of the
placenta praevia is novel.46) Although the presence of a
placenta praevia does not necessarily result in PPH that
cannot be treated with pharmacological agents, a study
involving women undergoing a CS for placenta previa
demonstrated a trend towards “benefit in placing a Bakri
balloon prophylactically at the time of CS”.47) However,
a statistically significant reduction in the need for
additional medical/surgical measures to control blood
loss, or a reduction in the subjective/objective blood loss
was not demonstrated.
The use of the balloon in a prophylactic modality may
also be useful in other situations. This may include the
use of balloons in patients who refuse blood products.
For example following complicated deliveries such
as retained products of conception requiring manual
removal in patients who refuse blood and blood products
even if the blood loss at the time of the original procedure
is not considered extreme (Case 6 Ref. 15).

Vaginal lacerations

Although uterine atony is the commonest cause of PPH,
PPH may also occur secondary to genital tract trauma.
During childbirth the vagina may experience multiple
lacerations and develop raw bleeding surfaces as well as
haematomas. Topical sutures and vaginal packing are the
traditional treatment methods that are employed.48)
However, there have been examples in which various

balloons have been used as a substitute for a vaginal
gauze pack.49 – 52) In such cases air may be used to
insufflate the balloons.
The potential advantage of using the balloons in these
situations includes that the balloon device will not absorb
blood that may otherwise result in a delay diagnosing
ongoing bleeding. Secondly, in balloons with a drainage
channel, ongoing blood loss may be continually assessed.

Prevention of recurrent uterine inversion

Uterine inversion is an obstetric situation that is
frequently followed by an atonic uterus and results in
a PPH. BTT (Rusch Balloon) has been used in these
situations following the re-establishment of normal
uterine anatomy.53) Unfortunately, in some cases uterine
inversion recurs and treatment of this uterine re-inversion,
using a Bakri balloon has also been described.54)
However, a novel approach is the use of a Bakri balloon
to prevent recurrence.55)

Lack of available (Blood) resources

In certain situations, although transfusion with blood and
blood products is indicated, it may not be possible due to
lack of local resources. Although the balloon is not a
blood substitute, the use of such a device may serve to
staunch the bleeding to facilitate whatever resuscitation is
possible (Diagram 1). Thus, the balloon may not only
provide a definitive treatment procedure, but may also
reduce the bleeding significantly to facilitate transfer of
the patient to another appropriate site.56)

Disseminated Intravascular Coagulopathy (DIC)

The Bakri balloon is not indicated for the use in the
presence of DIC.38) However, in such a situation the use
of the balloon may reduce the loss of blood to facilitate
resuscitation and correct the coagulopathy before a more
definitive procedure such as a re-laparotomy is performed.
For example following a recent caesarean with a PPH
suspected to be caused by genital tract trauma following
a failed tamponade test (See below; Unpublished data).

Negative tamponade test

The basis of the “tamponade test” in the management of
PPH will “identify those who will or will not need
surgery”.36) Failure of the tamponade test may be due to
a number of resons. This will include methodological
problems such as the failure to incorporate a clinical
outcome/assessment during insufflation of the balloon, or
other cause of PPH not amenable to BTT. The latter is
exemplified in case studies where failure of the
tamponade test has been associated with genital tract
trauma that was originally overlooked.10)
However, despite a negative tamponade test, the use
of BTT may result in continual bleeding at a slower
Hypertens Res Pregnancy 2014; 2: 1–10
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Table 3. Intraluminal pressures and corresponding blood pressure readings when a positive tamponade test was
achieved in seven cases (Reproduced from Georgiou, 2012.)31)
Case

Final volume (mls)
in balloon Positive
Tamponade Test

Corresponding
Intraluminal
pressure
(mmHg)

Range of patient’s
blood pressure
(Systolic /diastolic - mmHg)

Average
blood
pressure
(mmHg)

Average mean
arterial
pressure
(mmHg)

1
2
3
4
5
6
7

360
350
350
450
350
500
300

83
43
76
118
154
90
81

80–110/40–65
90–140/50–60
75–110/45–60
90–120/45–60
80–140/40–85
90–130/45–90
95–130/55–100

92/46
110/55
87/49
103/52
117/63
98/59
121/62

61
73
62
69
81
72
82

Insertion
T= 0hrs

Remove
remaining
T= 16-24hrs
Resuscitate

Remove 50%
T= 8-12hrs

Golden Hour

rate than if the balloon was absent. This may provide
an opportunity to resuscitate a patient before a proposed
laparotomy.

Mechanisms of action
Currently there are a number of proposed mechanisms by
which the balloons are thought to exert their “tamponade”
effect. The initial theory of the intrauterine balloon acting
by exerting in inward-to-outward pressure “that is greater
than the systemic arterial pressure” to prevent continual
bleeding has been challenged (Table 3).30,31) Studies of
actual intrauterine pressures do not suggest that this is
necessary, and alternative mechanisms of action have
been proposed. These include: hydrostatic pressure effect
6
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Diagram 1. Using a 24-h clock to manage
when to resuscitate the patient and plan
the removal of saline withtin the balloon
following the achievement of a positive
tamponade test.
T, time from successful tamponade test.
(Reproduced from Georgiou, 2009.)33)

on the uterine arteries, endometrial contact, vascular
compression via myometrial stretch and myometrial
activity secondary to myometrial stretching.30,31)
Recently, cervical dilation resulting in myometrial
activity has been demonstrated by electromyography.41)
This may serve to explain the effectiveness of the low
volume cervical ripening balloon positioned in the
lower uterine segment/cervical canal.22,44) Similarly,
obstructing the outflow of the uterus by cervical clamping
in the absence of a balloon, may allow the collection of
blood/clots within the uterus. This may also contribute to
the previously suggested mechanisms of action involving
lower uterine/cervical stetching.22,57,58)
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G2P1

G1P0

G4P3

G1P0

G1P0

NM

NM

NM

Gravity/
Parity

VB

VB

+2

39 + 4

37

VB

VB

37 + 5

37 + 2

VB

C/ S

C/ S

VB

Mode
of
delivery

39

NM

NM

NM

Gestation
(Weeks +
Days)

–

–

–

Manual
removal of
placenta,
atonic
uterus
Atonic
uterus
Manual
removal of
placenta,
atonic
uterus

–

Adherent
placenta,
manual
removal,
atonic
uterus

None

None

None

None

None

Cervical/
perineal
trauma

Atonic
uterus

2500 mls

2000 mls

Bakri
(450 mls)

Bakri
(250 mls)

1000 mls

3500 mls

2500 mls

2000–
3000 mls

2000–
3000 mls

4000 mls

PPH
Volume

Bakri
(400 mls)

Bakri
(400 mls)

Bakri
(450 mls)

Bakri
(60–250 mls)

B-Lynch
suture

–

Hypotonic
Uterus

Bakri
(60–250 mls)

Hypotonic
Uterus

B-Lynch
suture

–

“Morbidly
adherent
placenta”

BTT used
to stop
bleeding
(Vol
required)

Rusch
(500 mls)

–

Cause
of PPH

SLA used
prior
to BTT

SBT, Arterial
embolisation

Other
causes
of
bleeding

NM

NM

NM

Description
of periods

No
Breast
Feeding

Menses
at 6
weeks

Normal
(Frequency,
amount,
duration)

36

29

Afte
Normal
cessation (Frequency,
5 months
of breast
amount,
feeding
duration)

23

18

NM

NM

Within
3 yrs

Interval
to next
pregnancy
(Months)

15

Menses
at 8
weeks

Afte
Normal
cessation (Frequency,
amount,
of breast
feeding
duration)

Afte
Normal
cessation (Frequency,
of breast
amount,
feeding
duration)

NM

NM

NM

Return
of
periods

Normal
(Frequency,
amount,
duration)
7 weeks

10 weeks

8 weeks

NM

NM

NM

Breast
feeding
duration

Post-partum

VB

VB

VB

VB

40 + 3weeks

40 + 2weeks

37 + 0weeks

38 + 5weeks

39 + 1weeks

NM

Elective
C/S

VB

NM

NM

“another
normal
delivery”

NM

Gestation

Mode
of
delivery

250 mls

400 mls

400 mls

300 mls

1000
mls

NM

NM

NM

EBL at
delivery

Subsequent Pregnancy

–

–

Manual
removal of
placenta in
theatre.
Prophylactic
Bakri

Succenturiate
lobe

“complicated
by uterine
atony”
PPH
managed by
ergometrin
and
misoprosptol

“retained
placenta
but a less
dramatic
manual
removal”

Other
comments

PPH, postpartum haemorrhage; SLA, second line approaches; BTT, balloon tamponade technology; EBL, estimated blood loss; NM, not mentioned; VB, vaginal birth; C / S, caesarean section; SBT, Sengstaken-Blakemore tube.

31

28

5

8

26

4

25

NM

3(Ref. 61)

7

NM

2(Ref. 61)

28

19

1(Ref. 60)

6

Age

Case

Index pregnancy

Table 4. Subsequent menses, fertility and pregnancies from cases in which balloon tamponade technology was used in a preceding pregnancy as a
second-line approach for the management of PPH (Modified references within “Case” column refer to this publication. Reproduced from Georgiou, 2014.)15)
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Future pregnancies

estimated blood loss and coagulation profile.

An evaluation of women who experienced a PPH in their
first pregnancy did not result in a statistically significant
reduction in the proportion of these women returning for
a second pregnancy.59) That paper however, did not
specify the treatment modalities used to treat the PPH and
furthermore, the study evaluated women experiencing a
PPH at a time when BTT was being established into
clinical practice (1986–2005). Therefore, the subsequent
increase in BTT usage, particularly as a “uterine/fertility
sparing” option, is likely to generate repeat pregnancies.
In the published literature there is a single pregnancy
reported following the use of the multiple SLA
culminating in the successful use of a Rusch balloon and
two pregnancies following the use of a Bakri balloon in
combination with a failed B-Lynch suture.60,61) Recently,
five additional pregnancies have been described in
which a Bakri balloon is solely used as a SLA in the
management of PPH.15) In these cases information with
respect to menses fertility and pregnancy appear to
suggest minimal effect when using the Bakri balloon
(Table 4).15)
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Summary
PPH is a potentially life-threatening event in which a
number of SLA exist to compliment pharmacological
approaches. The choice of these SLA is usually dependent
on the availability of resources and technical ability of the
attending O&G specialist.
Initially, the use of BTT within this armamentarium
was as a “last resort” usually following more invasive
SLA such as embolization or vessel ligations.60)
Subsequently, combinations involving BTT were used.
For example the Bakri B-Lynch sandwich technique.61–63)
However, there are no comparative studies in which the
reverse order is considered, whereby a balloon is used
first and if unsuccessful, using a compression suture or
vascular ligation.
The use of BTT has proven to be a popular and
relatively simple technique with apparently minimal
side effects and complications. Although considered a
“fertility-sparing” option further long-term studies are
required, as well as comparison data to other SLA, to
determine whether BTT should be used as not only
the SLA of choice when FLU have failed, but also to
extend its repertoire of ‘indications of use” to include:
prophylaxis, assisting in resuscitation for causes other
than uterine atony and for the transfer of patients to more
resourceful locations.
Furthermore, It would not be unrealistic to consider
the use of BTT as a first choice after FLU have failed
regardless of the resource settings and irrespective of the
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